Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Gains from Investment Securities (2022 - 2025)

Historic Gains from Investment Securities for Indivior Pharmaceuticals (INDV) over the last 4 years, with Q1 2025 value amounting to $3.0 million.

  • Indivior Pharmaceuticals' Gains from Investment Securities fell 8500.0% to $3.0 million in Q1 2025 from the same period last year, while for Sep 2025 it was $5.0 million, marking a year-over-year decrease of 9390.24%. This contributed to the annual value of $22.0 million for FY2024, which is 0.0% changed from last year.
  • According to the latest figures from Q1 2025, Indivior Pharmaceuticals' Gains from Investment Securities is $3.0 million, which was down 8500.0% from $2.0 million recorded in Q4 2024.
  • Over the past 5 years, Indivior Pharmaceuticals' Gains from Investment Securities peaked at $62.0 million during Q4 2023, and registered a low of -$21.0 million during Q1 2023.
  • In the last 4 years, Indivior Pharmaceuticals' Gains from Investment Securities had a median value of $2.5 million in 2024 and averaged $7.2 million.
  • As far as peak fluctuations go, Indivior Pharmaceuticals' Gains from Investment Securities skyrocketed by 46363.64% in 2023, and later tumbled by 9677.42% in 2024.
  • Indivior Pharmaceuticals' Gains from Investment Securities (Quarter) stood at $11.0 million in 2022, then surged by 463.64% to $62.0 million in 2023, then plummeted by 96.77% to $2.0 million in 2024, then skyrocketed by 50.0% to $3.0 million in 2025.
  • Its Gains from Investment Securities was $3.0 million in Q1 2025, compared to $2.0 million in Q4 2024 and $20.0 million in Q1 2024.